Irisin Hormone as a Novel Diagnostic Marker for Detection and Progression of Diabetic Nephrophathy Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: HBa1c, glucose.
- Who it may be relevant to
- Registry conditions: Diabetic Nephropathies. Basic parameters: 30 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of Irisin as a Novel Diagnostic Marker for Early Detection and Progression of Diabetic Nephrophathy
Overview
Study the relation between irisin level and progression of diabetic nephropathy and its early detection.
Detailed description
Diabetes is a prevalent worldwide challenge affecting 425 million individuals, with the International Diabetes Federation (IDF) projecting a rise to 630 million by 2045. Diabetic nephropathy (DN) is a critical complication that impacts one-third of diabetic patients and significantly contributes to cardiovascular morbidity and mortality, leading to substantial socioeconomic burdens (Dwivedi and Sikarwar, 2024).
Diabetic nephropathy (DN) is a multifaceted condition involving various interconnected mechanisms, primarily influenced by hyperglycemia .
Diabetic nephropathy (DN) is one of the most feared diabetic chronic microvascular complications and the major cause of end-stage renal disease (ESRD).
Therefore, early recognition is crucial. Presently, this relies on the albumin excretion rate (AER) and glomerular filtration rate (GFR).
Irisin, an exercise - induced myokine, has been linked to metabolic disorders, but its relationship with DN remains unclear.
Experimental studies have demonstrated the role of irisin in protecting mice against diabetes and obesity
Interventions
- Diagnostic test HBa1c
Rapid method for detection of diabetes - Diagnostic test glucose
accurate method for diabetes
Primary outcome measures
- Measure number of Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ). [Time frame: Two years]
Eligibility criteria
Inclusion criteria
Type 2 diabetic patients
Exclusion criteria
- Non-diabetic kidney diseases.
- Acute illness, infection, obesity, hypertension, type 1 DM.
- Malignancy, other endocrine disorders, corticosteroid drugs, pregnancy, lactation.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-only
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07435480 · Soh-Med--26-2-1MD